Advertisement
U.S. markets open in 8 hours 58 minutes
S&P Futures
6,035.25 -3.00 (-0.05%) Dow Futures
44,968.00 +17.00 (+0.04%) Nasdaq Futures
20,957.75 -35.75 (-0.17%) Russell 2000 Futures
2,434.40 +2.00 (+0.08%) Crude Oil
68.84 +0.07 (+0.10%) Gold
2,640.10 +18.80 (+0.72%)
AstraZeneca PLC (ZEG.HA)
Hanover - Hanover Delayed Price. Currency in EUR
Follow
At close: 05:25PM CET
| Previous Close | 126.05 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 0.00 - 0.00 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Feb 06, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireTRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
WILMINGTON, Del., November 25, 2024--Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer
Simply Wall St.We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative
The market seemed underwhelmed by last week's earnings announcement from AstraZeneca PLC ( LON:AZN ) despite the...
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.